EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Pulsed Field Ablation Using Focal Contact Force–Sensing Catheters for Treatment of Atrial Fibrillation: 1-Year Outcomes of the ECLIPSE AF Study

Ante Anić iD, Thomas Phlips iD, Toni Brešković iD, Vikramaditya Mediratta iD, Steven Girouard iD, Zrinka Jurišić iD, Ivan Sikirić iD, Lucija Lisica iD, Pieter Koopman iD, Nathalie Antole, Johan Vijgen iD

Circulation: Arrhythmia and Electrophysiology · 2025-01 · 18 (1)

DOI: 10.1161/circep.124.012794 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Circulation: Arrhythmia and Electrophysiology, 2025-01. Verfasst von Ante Anić und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department for Cardiovascular Diseases, Klinički Bolnički Centar Split, Croatia (A.A., T.B., Z.J., I.S., L.L.). Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Pulmonary Veins, Cardiac Catheters. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pulsed field ablation (PFA) is a promising treatment for atrial fibrillation. We report 1-year freedom from atrial arrhythmia outcomes using monopolar PFA delivered through 3 commercial, contact force–sensing focal catheters. METHODS: ECLIPSE AF (Safety & Clinical Performance Study of Catheter Ablation With the Centauri System for Patients With Atrial Fibrillation; NCT04523545) was a prospective, single-arm, multicenter study evaluating acute and chronic safety and performance using the CENTAURI system to deliver focal PFA with TactiCath SE, StablePoint, and ThermoCool ST. Patients with paroxysmal or persistent atrial fibrillation underwent pulmonary vein (PV) isolation under deep sedation or general anesthesia and returned for remapping at 90 days to evaluate chronic durability. Freedom from atrial arrhythmia was evaluated continuously through 12 months using standard rhythm monitoring for symptomatic episodes and 24-hour Holter at 6 and 12 months. RESULTS: Eighty-two patients (74% male, 51.2% paroxysmal, and 58.5% deep sedation) were treated. PV isolation was achieved in 100% of targeted veins (322/322) with first-pass isolation in 92.2% (297/322). There were 4 primary safety events in 4 patients (4.9%, 4/82); 1 nonembolic stroke due to exacerbated cardiac tamponade secondary to catheter perforation and 3 hemorrhagic vascular access complications. There were no incidences of adverse event fistula, diaphragmatic paralysis, myocardial infarction, pericarditis, thromboembolism, PV stenosis, transient ischemic attack, or death. Eighty patients (98%) underwent remapping. Optimized PFA cohorts 3, 4, and 5 showed per-patient isolation rates of 60%, 73%, and 81% and per-PV isolation rates of 84%, 90%, and 92%, respectively. One-year freedom from atrial arrhythmia was 80.2% (95% CI, 69.7%–87.4%) for the entire patient sample, including 41 patients who underwent repeat focal PFA with the CENTAURI system at remapping. CONCLUSIONS: This study demonstrated that optimization of focal PFA with 3 contact force–sensing, solid-tip ablation catheters resulted in the progressive improvement of PV isolation durability at 3-month remapping and high freedom from atrial arrhythmia survival rates, providing a promising focal PFA treatment option integrated with current ablation workflows.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCatheter AblationPulmonary VeinsCardiac CathetersHeart RateHumansMaleFemaleProspective StudiesMiddle AgedAgedTreatment OutcomeTime FactorsEquipment DesignFollow-Up StudiesAction Potentials

Stichwörter der Autor:innen

atrial fibrillationelectrocardiography, ambulatoryfibrosisincidencepulmonary veins

Autor:innen und Institutionen

  • Department for Cardiovascular Diseases, Klinički Bolnički Centar Split, Croatia (A.A., T.B., Z.J., I.S., L.L.).
  • Department for Cardiovascular Diseases, Jessa Ziekenhuis, Hasselt, Belgium (T.P., P.K., N.A., J.V.).
  • CardioFocus, Inc, Marlborough, MA (V.M., S.G.).

ORCID-Profile: Ante Anić, Thomas Phlips, Toni Brešković, Vikramaditya Mediratta, Steven Girouard, Zrinka Jurišić, Ivan Sikirić, Lucija Lisica, Pieter Koopman, Johan Vijgen

Zitieren

APA

Anić, A., Phlips, T., Brešković, T., Mediratta, V., Girouard, S., Jurišić, Z., Sikirić, I., Lisica, L., Koopman, P., Antole, N., & Vijgen, J. (2025). Pulsed Field Ablation Using Focal Contact Force–Sensing Catheters for Treatment of Atrial Fibrillation: 1-Year Outcomes of the ECLIPSE AF Study. Circulation: Arrhythmia and Electrophysiology, 18(1). https://doi.org/10.1161/circep.124.012794

Vancouver

Anić A, Phlips T, Brešković T, Mediratta V, Girouard S, Jurišić Z, et al. Pulsed Field Ablation Using Focal Contact Force–Sensing Catheters for Treatment of Atrial Fibrillation: 1-Year Outcomes of the ECLIPSE AF Study. Circulation: Arrhythmia and Electrophysiology. 2025;18(1). doi:10.1161/circep.124.012794

BibTeX
@article{Ani2025,
  author = {Anić, Ante and Phlips, Thomas and Brešković, Toni and Mediratta, Vikramaditya and Girouard, Steven and Jurišić, Zrinka and Sikirić, Ivan and Lisica, Lucija and Koopman, Pieter and Antole, Nathalie and Vijgen, Johan},
  title = {Pulsed Field Ablation Using Focal Contact Force–Sensing Catheters for Treatment of Atrial Fibrillation: 1-Year Outcomes of the ECLIPSE AF Study},
  journal = {Circulation: Arrhythmia and Electrophysiology},
  year = {2025},
  volume = {18},
  number = {1},
  doi = {10.1161/circep.124.012794}
}
Kostenlos starten →